Libtayo (cemiplimab-rwlc) / Regeneron 
Welcome,         Profile    Billing    Logout  
 1 Disease   67 Trials   67 Trials   1555 News 


«12...345678910111213...3940»
  • ||||||||||  FDA event, Journal:  An Expedition on Synthetic Methodology of FDA-approved Anticancer Drugs (2018-2021). (Pubmed Central) -  Jan 30, 2024   
    The review comprises the key structural features, approval times, target selectivity, mechanisms of action, therapeutic indication, formulations, and possible synthetic approaches of these approved drugs. These crucial details will benefit the scientific community for futuristic new developments in this arena.
  • ||||||||||  Libtayo (cemiplimab-rwlc) / Regeneron
    TREATMENT OF ACUTE PERICARDITIS RELATED TO CEMIPLIMAB (Hall B4-5) -  Jan 26, 2024 - Abstract #ACC2024ACC_475;    
    In the setting of ICIs exposure, they are considered the first line option. Multidisciplinary evaluation led to identification and resolution of symptoms in our patient.
  • ||||||||||  Libtayo (cemiplimab-rwlc) / Regeneron
    Phase classification:  CONTRAC: Cemiplimab in AlloSCT/SOT Recipients With CSCC (clinicaltrials.gov) -  Jan 25, 2024   
    P1/2,  N=12, Active, not recruiting, 
    Multidisciplinary evaluation led to identification and resolution of symptoms in our patient. Phase classification: P1 --> P1/2
  • ||||||||||  Odomzo (sonidegib) / Sun Pharma, Libtayo (cemiplimab-rwlc) / Regeneron, Keytruda (pembrolizumab) / Merck (MSD)
    Combination of Upfront Systemic Therapy and Radiation in Advanced Non-Melanoma Skin Cancer (JW Marriott Desert Ridge Grand Canyon 6-8; Poster Screen #1) -  Jan 24, 2024 - Abstract #MHNCS2024MHNCS_268;    
    Results of KEYNOTE-630 will elucidate the role of adjuvant pembro among pts with high-risk, LA cSCC. Of 8 cSCC patients, 7 were treated with cemiplimab and 1 with pembrolizumab...All 7 BCC patients were treated with sonidegib for a duration of 205
  • ||||||||||  Review, Journal:  Advances and challenges of first-line immunotherapy for non-small cell lung cancer: A review. (Pubmed Central) -  Jan 23, 2024   
    Results from first-line trials have shown that almost all driver-negative mNSCLC are treated with ICIs and significantly prolong patient survival; however, the low response rate and adverse reactions to immunotherapy remain to be addressed. Here, we summarize the use of ICIs, including monotherapy and combination therapy, in the first-line treatment of mNSCLC in recent years and discuss the low response rate and adverse reactions of ICIs as well as the challenges and expectations for the first-line treatment of mNSCLC in the future.
  • ||||||||||  Libtayo (cemiplimab-rwlc) / Regeneron, Dupixent (dupilumab) / Sanofi, Regeneron
    Enrollment open, Trial initiation date:  Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC (clinicaltrials.gov) -  Jan 11, 2024   
    P1/2,  N=21, Recruiting, 
    No abstract available Not yet recruiting --> Recruiting | Initiation date: Oct 2023 --> Jan 2024
  • ||||||||||  Libtayo (cemiplimab-rwlc) / Regeneron
    Trial completion date:  CONTRAC: Cemiplimab in AlloSCT/SOT Recipients With CSCC (clinicaltrials.gov) -  Jan 3, 2024   
    P1,  N=12, Active, not recruiting, 
    Further studies are needed to evaluate ICIs in the management of CIN. Trial completion date: Jan 2024 --> Jan 2025
  • ||||||||||  Libtayo (cemiplimab-rwlc) / Regeneron, fianlimab (REGN3767) / Regeneron
    Enrollment closed:  LAG3 PET Imaging in Advanced Solid Tumors (clinicaltrials.gov) -  Jan 2, 2024   
    P1/2,  N=41, Active, not recruiting, 
    Trial completion date: Jan 2024 --> Jan 2025 Recruiting --> Active, not recruiting
  • ||||||||||  ISA101 / ISA Pharma
    Trial completion date, Trial primary completion date:  OpcemISA: A Randomized Phase 2 Study of Cemiplimab  (clinicaltrials.gov) -  Dec 29, 2023   
    P2,  N=194, Active, not recruiting, 
    Recruiting --> Active, not recruiting Trial completion date: Dec 2024 --> Jun 2025 | Trial primary completion date: Sep 2023 --> Sep 2024
  • ||||||||||  REGN6569 / Regeneron, Libtayo (cemiplimab-rwlc) / Regeneron
    Enrollment open, Trial primary completion date:  Study of REGN6569 and Cemiplimab in Adult Patients With Advanced Solid Tumor Malignancies (clinicaltrials.gov) -  Dec 22, 2023   
    P1,  N=85, Recruiting, 
    Trial completion date: Dec 2024 --> Jun 2025 | Trial primary completion date: Sep 2023 --> Sep 2024 Active, not recruiting --> Recruiting | Trial primary completion date: Jul 2026 --> Apr 2025
  • ||||||||||  tolododekin alfa (ANK-101) / Ankyra Therap
    Enrollment open:  ANCHOR: Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors (clinicaltrials.gov) -  Dec 17, 2023   
    P1,  N=46, Recruiting, 
    These findings provide valuable insights into the real-world effectiveness of cemiplimab in SCC management. Not yet recruiting --> Recruiting
  • ||||||||||  SAR444200 / Sanofi
    Trial completion date, Trial primary completion date, Metastases:  Dose Escalation and Expansion Study of SAR444200-based Regimen in Adult Participants With Advanced Solid Tumors (clinicaltrials.gov) -  Dec 7, 2023   
    P1/2,  N=106, Recruiting, 
    Finally, Hedgehog pathway inhibitors and checkpoint inhibitors, must be thoroughly investigated with large controlled trials, since they may offer an alternative solution to irresectable or difficult-to-treat locally advanced cases of basosquamous carcinoma. Trial completion date: May 2030 --> Dec 2030 | Trial primary completion date: May 2030 --> Dec 2030
  • ||||||||||  Libtayo (cemiplimab-rwlc) / Regeneron
    ISS-01: Personalizing Treatment for Adult Patients with Advanced NSCLC (Chicago Ballroom ABCD) -  Nov 29, 2023 - Abstract #IASLCNACLC2023IASLC_NACLC_88;    
    The presentation will outline clinical evidence and important safety data for Libtayo, review a patient case study with advanced NSCLC and explore how to initiate treatment with Libtayo in appropriate patients. The program is sponsored and content developed by Regeneron Pharmaceuticals, Inc.
  • ||||||||||  Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
    Journal, Metastases:  Favorable efficacy of S-1 treatment for locoregionally advanced cutaneous squamous cell carcinoma in the head and neck region. (Pubmed Central) -  Nov 28, 2023   
    Although recent guidelines from Western countries recommend using anti-programmed cell death protein 1 (PD-1) antibodies, including cemiplimab and pembrolizumab, there are no approved anti-PD-1 antibodies for locoregional cutaneous squamous cell carcinoma in Asian countries...S-1 showed favorable efficacy and low toxicity in patients with head and neck locoregionally advanced cutaneous squamous cell carcinoma. S-1 may be a good alternative to the anti-PD-1 antibody for treating head and neck locoregionally advanced squamous cell carcinoma.